Pharmaceutical composition for cancer treatment comprising fusion protein including il-12 and anti-fap antibody and anticancer agent

Abstract

The present invention provides a combined therapeutic agent of: a fusion protein comprising IL-12 or a variant thereof and an antigen-binding site that specifically binds to FAP; and an anticancer agent. The bispecific antibody exhibits an anticancer effect by IL-12 and in particular, when the anti-FAP antibody is realized in one antibody, cancer can be efficiently treated by targeting FAP expressed highly specifically in a tumor and specifically localizing IL-12 to a tumor site. When the fusion protein is administered in combination with a known anticancer agent, there is a synergistic effect on anticancer treatment.

Dependencies are inferred from the claim text.